TCON
Income statement / Annual
Last year (2023), TRACON Pharmaceuticals, Inc.'s total revenue was $12.05 M,
and the percentage change from the previous year is not available.
In 2023, TRACON Pharmaceuticals, Inc.'s net income was -$3.59 M.
See TRACON Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$12.05 M |
$0.00 |
$346.00 K |
$0.00 |
$0.00 |
$3.00 M |
$8.76 M |
$3.45 M |
$7.90 M |
$3.60 M |
| Cost of Revenue |
$14.00 K
|
$16.00 K
|
$14.00 K
|
$12.00 K
|
$22.00 K
|
$30.46 M
|
$19.36 M
|
$15.24 M
|
$20.43 M
|
$4.85 M
|
| Gross Profit |
$12.03 M
|
-$16.00 K
|
$332.00 K
|
-$12.00 K
|
-$22.00 K
|
-$27.46 M
|
-$10.60 M
|
-$11.80 M
|
-$12.53 M
|
-$1.26 M
|
| Gross Profit Ratio |
1
|
0
|
0.96
|
0
|
0
|
-9.15
|
-1.21
|
-3.42
|
-1.58
|
-0.35
|
| Research and Development Expenses |
$12.28 M
|
$13.89 M
|
$11.15 M
|
$8.20 M
|
$14.53 M
|
$30.46 M
|
$19.36 M
|
$21.57 M
|
$25.68 M
|
$7.65 M
|
| General & Administrative Expenses |
$6.67 M
|
$14.01 M
|
$17.55 M
|
$8.03 M
|
$7.77 M
|
$7.28 M
|
$7.61 M
|
$7.86 M
|
$5.69 M
|
$2.13 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.67 M
|
$14.01 M
|
$17.55 M
|
$8.03 M
|
$7.77 M
|
$7.28 M
|
$7.61 M
|
$7.86 M
|
$5.69 M
|
$2.13 M
|
| Other Expenses |
$0.00
|
-$1.24 M
|
-$320.00 K
|
-$7.00 K
|
-$378.00 K
|
$12.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$18.93 M
|
$27.89 M
|
$28.69 M
|
$16.22 M
|
$22.30 M
|
$37.74 M
|
$26.97 M
|
$29.43 M
|
$31.37 M
|
$9.78 M
|
| Cost And Expenses |
$18.94 M
|
$27.89 M
|
$28.69 M
|
$16.22 M
|
$22.30 M
|
$37.74 M
|
$26.97 M
|
$29.43 M
|
$31.37 M
|
$9.78 M
|
| Interest Income |
$0.00
|
$994.00 K
|
$318.00 K
|
$545.00 K
|
$386.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$7.30 M
|
$994.00 K
|
$318.00 K
|
$545.00 K
|
$386.00 K
|
$231.00 K
|
$886.00 K
|
$1.12 M
|
$923.00 K
|
$667.00 K
|
| Depreciation & Amortization |
$14.00 K
|
$16.00 K
|
$14.00 K
|
$12.00 K
|
$22.00 K
|
$28.00 K
|
$48.00 K
|
$94.00 K
|
$51.00 K
|
$15.00 K
|
| EBITDA |
-$6.88 M |
-$27.89 M |
-$28.33 M |
-$16.22 M |
-$22.27 M |
-$34.71 M |
-$18.17 M |
-$25.80 M |
-$23.42 M |
-$6.16 M |
| EBITDA Ratio |
-0.57
|
0
|
-81.89
|
0
|
0
|
-11.57
|
-2.08
|
-7.48
|
-2.96
|
-1.71
|
| Operating Income Ratio |
-0.57
|
0
|
-81.93
|
0
|
0
|
-11.58
|
-2.08
|
-7.53
|
-2.97
|
-1.72
|
| Total Other Income/Expenses Net |
$3.31 M
|
-$1.24 M
|
-$320.00 K
|
-$552.00 K
|
-$378.00 K
|
-$219.00 K
|
-$893.00 K
|
-$1.03 M
|
-$943.00 K
|
-$630.00 K
|
| Income Before Tax |
-$3.59 M
|
-$29.14 M
|
-$28.67 M
|
-$16.78 M
|
-$22.67 M
|
-$34.96 M
|
-$19.10 M
|
-$27.01 M
|
-$24.41 M
|
-$6.81 M
|
| Income Before Tax Ratio |
-0.3
|
0
|
-82.85
|
0
|
0
|
-11.65
|
-2.18
|
-7.83
|
-3.09
|
-1.89
|
| Income Tax Expense |
$0.00
|
$177.00 K
|
$59.00 K
|
$551.00 K
|
-$16.00 K
|
$12.00 K
|
$845.00 K
|
$938.00 K
|
$892.00 K
|
$615.00 K
|
| Net Income |
-$3.59 M
|
-$29.31 M
|
-$28.73 M
|
-$17.33 M
|
-$22.66 M
|
-$34.96 M
|
-$19.10 M
|
-$27.01 M
|
-$24.41 M
|
-$6.81 M
|
| Net Income Ratio |
-0.3
|
0
|
-83.02
|
0
|
0
|
-11.65
|
-2.18
|
-7.83
|
-3.09
|
-1.89
|
| EPS |
-2.2 |
-28.02 |
-33.3 |
-38.63 |
-149.35 |
-259.47 |
-227.33 |
-426.06 |
-439.2 |
-113.7 |
| EPS Diluted |
-2.19 |
-28.02 |
-33.3 |
-38.57 |
-149.35 |
-259.47 |
-227.33 |
-426.06 |
-439.2 |
-113.7 |
| Weighted Average Shares Out |
$1.63 M
|
$1.05 M
|
$862.63 K
|
$448.53 K
|
$151.72 K
|
$134.73 K
|
$84.03 K
|
$63.39 K
|
$55.58 K
|
$59.89 K
|
| Weighted Average Shares Out Diluted |
$1.64 M
|
$1.05 M
|
$862.63 K
|
$449.21 K
|
$151.72 K
|
$134.73 K
|
$84.03 K
|
$63.39 K
|
$55.58 K
|
$59.89 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
